Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
80°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
27.46
+1.35 (+5.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akero Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Big Pharma Could Transform Into BioTech Pharma
October 10, 2023
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 10, 2023
Via
Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 10, 2023
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.
Via
Benzinga
4 Analysts Have This to Say About Akero Therapeutics
September 19, 2023
Via
Benzinga
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
June 09, 2023
Via
Investor Brand Network
S&P 500 Rises 1%; US Wholesale Inventories Fall In August
October 10, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Akero Therapeutics Stock Is Crashing Today
October 10, 2023
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
Via
The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
October 10, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today?
October 10, 2023
Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to
Via
Benzinga
Why Is Ocugen (OCGN) Stock Up 5% Today?
October 10, 2023
Ocugen stock is rising higher on Tuesday thanks to OCGN investors celebrating news of a new clinical trial for its Covid-19 vaccine.
Via
InvestorPlace
Exposures
COVID-19
NET Stock Alert: Cloudflare Discovers New Cyber Vulnerability
October 10, 2023
Cloudflare stock is getting a boost on Tuesday as investors in NET react to the cybersecurity company discovering a new vulnerability.
Via
InvestorPlace
US Stocks Gain; PepsiCo Posts Upbeat Earnings
October 10, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
October 10, 2023
Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results.
Via
InvestorPlace
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
October 10, 2023
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 10, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 10, 2023
It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning!
Via
InvestorPlace
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
October 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
October 09, 2023
Via
Benzinga
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
October 09, 2023
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
October 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
August 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
August 28, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Over $15.5M Bet On ModivCare? Check Out These 4 Stocks Insiders Are Buying
August 11, 2023
Although U.S. stocks closed slightly higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 11, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Over $2M Bet On Akero Therapeutics? Check Out These 3 Stocks Insiders Are Buying
August 02, 2023
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
June 23, 2023
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses
From
Akero Therapeutics
Via
GlobeNewswire
3 Mid Caps You Haven't Heard Of But Need To Know About
June 09, 2023
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration.
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.